Brodalumab

Identification

Summary

Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.

Brand Names
Siliq
Generic Name
Brodalumab
DrugBank Accession Number
DB11776
Background

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Brodalumab
External IDs
  • AMG 827
  • AMG-827
  • KHK-4827
  • KHK4827

Pharmacology

Indication

Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Increase in the level of IL-17 due to blocking of its receptors.

Mechanism of action

Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.

Absorption

Not Available

Volume of distribution

4.62 L.

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

0.223 L/day.

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Brodalumab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Brodalumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Brodalumab.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Brodalumab.
AducanumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Aducanumab.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Brodalumab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Brodalumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brodalumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Brodalumab.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Brodalumab.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
KyntheumInjection, solution210 mgSubcutaneousLeo Pharma2020-12-22Not applicableEU flag
KyntheumInjection, solution210 mgSubcutaneousLeo Pharma2020-12-22Not applicableEU flag
SiliqSolution210 mg / 1.5 mLSubcutaneousBausch Health, Canada Inc.2018-07-05Not applicableCanada flag
SiliqInjection210 mg/1SubcutaneousBausch Health US LLC2017-02-15Not applicableUS flag

Categories

ATC Codes
L04AC12 — Brodalumab
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
6ZA31Y954Z
CAS number
1174395-19-7

References

General References
  1. article [Link]
  2. article [Link]
KEGG Drug
D10061
PubChem Substance
347911240
RxNav
1872251
Wikipedia
Brodalumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPsoriasis (PsO)1
4CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
4CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis) / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular; Psoriasis, Palmaris Et Plantaris1
4Not Yet RecruitingTreatmentModerate to Severe Plaque Psoriasis1
4Not Yet RecruitingTreatmentPalmoplantar Psoriasis1
4Not Yet RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
4RecruitingTreatmentPsoriasis (PsO)2
4RecruitingTreatmentPsoriasis (PsO) / Psoriasis Vulgaris (Plaque Psoriasis)2
3Active Not RecruitingTreatmentModerate to Severe Systemic Sclerosis1
3Active Not RecruitingTreatmentPalmoplantar Pustulosis (PPP)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionParenteral; Subcutaneous210 MG
Injection, solutionSubcutaneous210 mg
InjectionParenteral
Injection, solutionSubcutaneous210 mg/1.5mL
InjectionSubcutaneous210 mg/1
SolutionSubcutaneous210 mg / 1.5 mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 20:47 / Updated on September 25, 2021 16:29